Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / TSPO



This biomarker is also known as:
  • Peripheral-type benzodiazepine receptor,
  • mitochondrial benzodiazepine receptor,
  • BZRP,
  • PKBS,
  • translocator protein,
  • benzodiazepine peripheral binding site,
  • PBR,
  • DBI,
  • peripheral-type benzodiazepine receptor,
  • PTBR,
  • PBS,
  • BPBS,
  • MBR,
  • PBRS,
  • translocator protein (18kDa),
  • benzodiazapine receptor (peripheral),
  • Mitochondrial benzodiazepine receptor,
  • pk18,
  • IBP,
  • mDRC,

View in BioMuta


TSPO is a conserved protein found at the outer mitochondrial membrane. TSPO interacts with some benzodiazepines and isoquinoline carboxamides and has different affinities than its endogenous counterpart. TSPO is also involved in the transport of porphyrins and heme.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


The TSPO gene is known to be over-expressed in highly aggressive tumors, especially those of the breast. Increasing levels of the TSPO protein are correlated with more advanced stages of breast cancer. Higher TSPO levels are found in estrogen receptor (ER)-negative breast tumors, compared with ER-positive tumors.

Performance Comment

TSPO was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014

Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.